Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NQ1S
|
|||
| Drug Name |
JNJ-78278343
|
|||
| Synonyms |
JNJ-8343
Click to Show/Hide
|
|||
| Drug Type |
Bispecific antibody
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1 | [1] | |
| Company |
Janssen Research & Development Raritan, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [1] |
| Tissue kallikrein (KLK2) | Target Info | . | [1] | |
| KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Coregulation of Androgen receptor activity | |||
| Regulation of Androgen receptor activity | ||||
| Reactome | Activation of Matrix Metalloproteinases | |||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | ||||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| WikiPathways | Prostate Cancer | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04898634) A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.